IPO News | Biotech company Hua Jian Future-B has launched its IPO, scheduled to list on June 23, with a minimum subscription amount of HK$8,262.49 per board lot

Futu News, June 12: $HJ SCIENCE-B (06132.HK)$ The company announced that the IPO will be open for subscription from June 12 to June 17, offering approximately 13.6 million shares globally, with listing expected on June 23.

Company Overview

Hua Jian Future was founded by a team of industry experts dedicated to developing therapies for autoimmune, metabolic, and oncology diseases. By identifying clinical needs and working backward from desired outcomes, the company aims to deliver improved therapeutic solutions. It has established a small-molecule drug development platform that integrates computational modeling with experimental drug design and screening, targeted and rapid drug-likeness assessment, and efficient CMC development and clinical research. Using this integrated approach, the company has advanced multiple differentiated drug candidates across various therapeutic areas.

The company has built a comprehensive R&D system covering drug design, in vitro and in vivo activity evaluation, drug metabolism, synthesis, quality research, formulation development, and scale-up. This end-to-end capability enables the company to effectively manage the entire drug development process—from molecule selection to clinical trials—giving it a unique competitive edge and enhanced efficiency in drug discovery and development.

Financial Summary

Hua Jian Future reported losses of RMB 202.3 million and RMB 135.1 million in 2024 and 2025, respectively. Revenue for 2024 and 2025 amounted to RMB 1.8 million and RMB 13.0 million, respectively, all derived from out-licensing and collaboration agreements. R&D expenses were RMB 75.0 million and RMB 110.2 million in 2024 and 2025, respectively.

Use of Proceeds

Regarding the use of proceeds, Huajian Future expects the net proceeds from the global offering to be approximately HK$1.019 billion (assuming the over-allotment option is not exercised and calculated based on the offer price of HK$81.80 per share). According to the prospectus, Huajian Future intends to allocate the proceeds from the global offering as follows:

Approximately 80.6% will be used to fund ongoing and planned clinical research and development activities for the company’s pipeline products; approximately 9.4% will be allocated to enhance the company’s R&D platform to strengthen its innovative pipeline in immunology, metabolism, and oncology, as well as to discover and develop new preclinical drug candidates to broaden its current therapeutic offerings; approximately 5% will be used to gradually build the company’s commercialization team and expand it as its drug candidates approach commercialization, ensuring effective market expansion and support upon product launch; and approximately 5% will be used for general corporate purposes and working capital.

Further reading:Huajian Future-B Prospectus

The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>

Editor/Joe

52K Views